Friday, 2 March 2018

Audit report: USFDA issued Nine 483s to Aurobindo Unit-4

USFDA issued Nine 483s to Aurobindo Unit-4






*USFDA issued Nine 483s to Aurobindo Unit-4*




Home Inspections USFDA issued Nine 483s to Aurobindo Unit-4

USFDA issued Nine 483s to Aurobindo Unit-4

March 2, 2018 abhishek kumar killiInspections

USFDA issued Nine 483s to Aurobindo Unit 4 in its latest inspection conducted from Feb 12th to 20th. CNBC-TV18 accesses the form 483 and had briefed 7 out of 9 observations in the microblogging website (Twitter) however, no official information has been received from Aurobindo. The site was inspected by FDA inspector Yasamin Ameri, a chemist / biologist;  who is competent in auditing areas like process validation, computer system etc.

*Details of few observations are given below:*

*1)* Buildings used to manufacture and storage of drugs are not free of rodents, birds and insects.

*2)* Employees engaged in manufacturing, processing, packing lack training

*3)* Statistical Quality Control criteria fail to include appropriate acceptance & rejection levels.

*4)* Established lab control mechanisms not followed & documented at the time of performance

*5)* Appropriate controls not exercised over computers or related systems

*6)* Aseptic processing areas deficient of systems used to control aseptic conditions

*7)* Equipment & utensils not cleaned & sanitized at appropriate intervals

The man scope of this audit was confined to review of the batch records and the investigations pertained to potential Class I recalls of its 04 Injectable products. The company has to respond with a detail compliance plan for all the observations issued in not less than 15 days from the last day of inspection.
________________________